TD Cowen Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its target price dropped by stock analysts at TD Cowen from $72.00 to $70.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “hold” rating on the medical research company’s stock. TD Cowen’s price objective indicates a potential upside of 17.33% from the stock’s previous close.

A number of other brokerages also recently commented on BRKR. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. The Goldman Sachs Group lowered their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Citigroup lowered their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Wells Fargo & Company lowered their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.82.

Bruker Trading Down 2.7 %

NASDAQ BRKR traded down $1.68 during trading on Wednesday, hitting $59.66. The stock had a trading volume of 758,867 shares, compared to its average volume of 1,065,792. The company has a market capitalization of $9.03 billion, a PE ratio of 24.68, a PEG ratio of 2.32 and a beta of 1.20. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. The firm has a 50 day moving average price of $64.08 and a 200 day moving average price of $66.56. Bruker has a twelve month low of $54.55 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business’s revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.74 earnings per share. As a group, equities research analysts forecast that Bruker will post 2.61 earnings per share for the current year.

Institutional Investors Weigh In On Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Covestor Ltd lifted its stake in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. lifted its stake in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in Bruker in the second quarter valued at approximately $52,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Bruker by 40.7% during the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after purchasing an additional 248 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.